Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Novo provides update on the denecimig Biologics License Application (BLA) in the USCompanies: Novo NordiskBagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
- ORIC PharmaceuticalsORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.
- Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the “Notes”) that the Notes are convertible, at the option of the holders (the “Conversion Option”) beginning on October 1, 2026, and ending at the close of business on December 31, 2026. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Notes being converted. Any determination regarding the convertibility of the Notes during future periods will be made in accordance with the terms of the Indenture governing the Notes.
- Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on October 1, 2026, the compensation committee of Apnimed’s board of directors granted 19 new non-executive employees non-qualified stock options to purchase an aggregate of 481,300 shares of the Company’s common stock under Apnimed’s 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $22.54, which is equal to Apnimed’s closing trading price on the grant date. One-fourth of the shares underlying each of the employee’s stock options will vest on the first anniversary of each employee’s start date and in equal monthly installments thereafter for the next three years, subject to such employee’s continued employment with the Company on such vesting dates.
- Outpost Technologies CorpExobiosphere to Become the First Commercial Customer of Outpost's New Space Factories, Bringing Microgravity Drug Discovery to Orbit and BackSpace biotech leader Exobiosphere will fly its Orbital High-Throughput System as the first customer module on Outpost's Space Factories platform — pairing repeatable microgravity access with reliable Earth return. LOS ANGELES, Oct. 2, 2026 -- Outpost Technologies Corporation...
- Rice UniversityRice Biotech Launch Pad invents 'living pharmacy' designed to produce therapeutics inside the bodyDurable implant to enter clinic in 2027 has multiple applications and represents new therapeutic approach that lasts full year — Biologic medicines can be powerful treatments for many diseases, but their cost can limit access. According to the U.S. Food...
- ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share CapitalTOULOUSE, France, October 02, 2026--Regulatory News: ABIONYX Pharma (Paris:ABNX):
- Klick Health Named MM+M Market Access Gold Agency of the YearNEW YORK & TORONTO, October 02, 2026--Klick Health took center stage throughout the evening at last night’s Medical Marketing + Media (MM+M) Awards, receiving the Market Access Gold Agency of the Year title plus nine campaign accolades, including five Gold trophies for "867-5309" (Cancer Support Community), "Project Inchstone" (Nestlé Compleat), and "MODDEN 26" (The Derek Sheely Foundation).
- Populus Health TechnologiesPopulus Health Technologies Announces New CROPRINCETON, N.J., October 02, 2026--Populus Health Technologies, a virtual care media and technology company, today announced the appointment of a new Chief Revenue Officer, Joe Catalano. As part of his new role, Catalano is responsible for planning and executing Populus’ sales and revenue strategy.
- Kaplan Fox Notifies Investors of Hims & Hers Health, Inc. (NYSE: HIMS) of a Securities Fraud Class Action Deadline on November 2, 2026Kaplan Fox announces a securities class action against Hims & Hers Health (NYSE: HIMS) for investors from Aug. 4, 2025 to July 29, 2026.